ClinicalTrials.gg
RecruitingNCT02934477Updated Aug 30, 2023

Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

An observational study in Myelofibrosis, sponsored by Center for International Blood and Marrow Transplant Research. Recruiting at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2023-08-30.

Sponsored by Center for International Blood and Marrow Transplant Research · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
650
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 454 studies in Primary Myelofibrosis with a site in United States — 70 open to participants now, 105 under way, 12 of them phase 3. Primary Myelofibrosis · United States.

Planned enrollment
11th of 35
650 · median 153
Started
2016
with 13 others
Observational
35 of 454
7 open now
Primary completion
2026-11
later than 26 of 104 live
Registered
300th of 454
by date

Among the 454 studies in Primary Myelofibrosis with a site in United States, this one is the 11th largest by planned enrollment of the 35 observational ones that give a count, is one of 14 that started in 2016, is one of 35 observational ones, reaches primary completion later than 26 of the 104 other live ones, and was the 300th registered.

Primary Myelofibrosis

628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

70 of the 454 studies in Primary Myelofibrosis with a site in United States are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Primary Myelofibrosis with a site in United States, or all of them as a file.
02

Study summary

This observational study will compare outcomes of a prospectively-enrolled cohort of Hematopoietic Stem Cell Transplant (HCT) recipients with outcomes of a cohort of age-matched historical non-HCT controls. Patients undergoing alloHCT will receive HCT in a US transplant center and be reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) using well-established CIBMTR report forms and data collection procedures as well as a study-specific supplemental form. Data on the historical non-HCT controls will be collected at 14 US academic centers. These centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.

Read the detailed description

Patients with primary MF (PMF), post-essential thrombocythemia (ET) MF, or post-polycythemia vera (PV) MF, with intermediate-2 or high-risk disease as determined by the DIPSS, and aged ≥55 at the time of DIPSS assessment are eligible for this study. For the allogeneic HCT arm of the HLA-Matched Donor HCT Study, donors must be either 6/6 HLA-matched related donors, defined by Class I (HLA-A and -B) intermediate resolution or high resolution DNA-based typing and Class II (HLA-DRBI) at high resolution DNA-based typing (but not monozygotic twins), OR an 8/8 HLA-A, -B, -C, and -DRB1 at high resolution DNA-based typing matched unrelated donors; both peripheral blood stem cells and bone marrow grafts are allowed, and all conditioning regimen intensities and graph versus host disease (GVHD) prophylaxis regimens are allowed. For the Haploidentical Donor Study, donors must be haploidentical.

This study will target accrual of 650 patients receiving alloHCT, including approximately 225 receiving myeloablative conditioning. Participating centers are expected to provide data for approximately 2,400 patients to form the non-HCT historical control cohort.

03

Conditions studied

  • Myelofibrosis

Browse trials for

Keywords

  • Myelofibrosis
  • Hematopoietic Stem Cell Transplant
  • Medicare
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with primary MF (PMF), post-essential thrombocythemia (ET) MF, or post-polycythemia vera (PV) MF, with intermediate-2 or high-risk disease as determined by the DIPSS, and aged ≥55 at the time of DIPSS assessment are eligible for this study. For the alloHCT arm of the HLA-Matched Donor HCT Study, donors must be either 6/6 HLA-matched related donors, defined by Class I (HLA-A and -B) intermediate resolution or high resolution DNA-based typing and Class II (HLA-DRBI) at high resolution DNA-based typing (but not monozygotic twins), OR an 8/8 HLA-A, -B, -C, and -DRB1 at high resolution DNA-based typing matched unrelated donors; both peripheral blood stem cells and bone marrow grafts are allowed, and all conditioning regimen intensities and GVHD prophylaxis regimens are allowed. For the Haploidentical Donor Study, donors must be haploidentical.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients fulfilling the following criteria will be eligible for inclusion in the study:

    • PMF, post-ET MF, or post-PV MF.
    • Int-2 or high-risk disease as determined by the DIPSS.
    • Age ≥55 at the time of DIPSS assessment.
    • For the alloHCT arm:

      • Donors must be a 6/6 HLA-matched related donors, defined by Class I (HLA-A and -B) intermediate resolution or high resolution DNA-based typing and Class II (HLA-DRBI) at high resolution DNA-based typing (but not monozygotic twins) OR an 8/8 HLA-A, -B, -C, and -DRB1 at high resolution DNA-based typing matched unrelated donor identified through the National Marrow Donor Program (NMDP)/Be The Match. Donors must meet institutional or NMDP/Be The Match selection criteria; there is no age restriction for sibling donors.
      • Both peripheral blood stem cells and bone marrow grafts are allowed.
      • All conditioning regimen intensities are allowed.
      • All prophylaxis regimens are allowed.
    • Haploidentical donors are allowed in the Haploidentical Donor Study

Exclusion criteria

Exclusion Criteria:

  • Patients with the following criteria will be ineligible for entry into the study:

    • AlloHCT using umbilical cord blood unit(s) or HLA-mismatched adult donors (\< 6/6 HLA alleles for related and \< 8/8 HLA alleles for unrelated).
    • Overlap syndromes.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
650 participants (estimated)
Patient registry
No

Groups and cohorts

  • Hematopoietic Stem Cell Transplant (HCT)

    Patients undergoing alloHCT in a US transplant center and reported to the CIBMTR

    Other: Hematopoietic Stem Cell Transplant

  • Non-HCT

    Historical non-transplant controls collected from 14 US academic centers. Centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.

Interventions

  • OtherHematopoietic Stem Cell Transplant

    This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of age-matched non-HCT controls.

06

What researchers measure

Primary outcomes

  1. Compare five year survival

    Compare the five-year survival probabilities from DIPSS assessment between the two study arms: alloHCT recipients (arm 1) and non-HCT therapies (ruxolitinib / best supportive care) recipients (arm 2).

    Time frame: Five years post transplant

Secondary outcomes

  1. Compare leukemia-free survival

    Compare leukemia-free survival at five years from DIPSS assessment date to the date of progression to AML or death from any cause, whichever comes first. Two co-secondary analyses will be conducted, one for all alloHCT patients versus Arm 2 and one for the subset of patients receiving MAC prior to alloHCT versus Arm 2. Observation is censored at the date of last follow-up for patients known to be alive without leukemia. Progression to AML is defined as \>20% leukemia blasts in bone marrow or in the peripheral blood.

    Time frame: Five years post transplant

  2. Cumulative incidences of chronic GVHD

    Occurrence of symptoms in any organ system fulfilling the criteria of chronic GVHD. Patients are censored at last follow-up or second transplant.

    Time frame: Five years post transplant

  3. Cumulative incidences of acute GVHD

    Occurrence of grade II, III, and/or IV skin, gastrointestinal, or liver abnormalities fulfilling the Consensus criteria of acute GVHD. Patients are censored at last follow-up or second transplant.

    Time frame: Five years post transplant

  4. Cumulative incidence of treatment related mortality

    Death from any cause in the first 28 days post-transplantation, irrespective of relapse status. Death beyond day +28 will only be considered transplant-related if the disease is in remission. This event will be summarized as a cumulative incidence estimate with relapse/persistence as the competing risk.

    Time frame: Five years post transplant

  5. The impact of certain patient, disease and HCT related factors on survival in the alloHCT arm.

    Evaluation of the impact of response to ruxolitinib therapy, patient age (\<65 years vs. \>= 65 years, disease duration and DIPSS on overall survival in the alloHCT arm. The time to event in the analyses will start at the time of transplant.

    Time frame: Five years post transplant

  6. The impact of certain patient, disease and HCT related factors on leukemia free survival in the alloHCT arm.

    Evaluation of the impact of response to ruxolitinib therapy, patient age (\<65 vs. \>= 65 years), disease duration and DIPSS on leukemia free survival in the alloHCT arm. The time to event in the analyses will start at the time of transplant.

    Time frame: Five years post transplant

  7. The impact of certain patient, disease and HCT related factors on hematopoietic recovery in the alloHCT arm.

    Evaluation of the impact of response to ruxolitinib therapy, patient age (\<65 vs \>=65 years), disease duration and DIPSS on hematopoietic recovery in the alloHCT arm. The time to event in the analyses will start at the time of transplant.

    Time frame: Five years post transplant

  8. The impact of certain patient, disease and HCT related factors on acute and chronic GVHD in the alloHCT arm.

    Evaluation of the impact of response to ruxolitinib therapy, patient age (\<65 vs \>= 65 years), disease duration and DIPSS on acute and chronic GVHD in the alloHCT arm. The time to event in the analyses will start at the time of transplant.

    Time frame: Five years post transplant

  9. The impact of certain patient, disease and HCT related factors on treatment related mortality in the alloHCT arm.

    Evaluation of the impact of response to ruxolitinib therapy, patient age (\<65 vs \>=65 years), disease duration, and DIPSS on treatment related mortality in the alloHCT arm. The time to event in the analyses will start at the time of transplant.

    Time frame: Five years post transplant.

  10. The impact of certain patient, disease and HCT related factors on relapse.

    Evaluation of the impact of response to ruxolitinib therapy, patient age (65 vs \>=65 years), disease duration and DIPSS on relapse in the alloHCT arm. The time to event in the analyses will start at the time of transplant.

    Time frame: Five years post transplant.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2016, a primary completion of Nov 2026 and a completion of Oct 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2016
First posted
Oct 17, 2016
Start
Nov 2016
Primary completionEst.
Nov 2026
CompletionEst.
Oct 2027
Last update
Aug 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02934477
Lead sponsor
Center for International Blood and Marrow Transplant Research
Collaborators
National Marrow Donor Program, National Institutes of Health (NIH), National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Oct 17, 2016
Start date
Nov 2016
Primary completion
Nov 2026 (estimated)
Completion
Oct 2027 (estimated)
Last update
Aug 30, 2023

Study contacts

Patricia Steinert, PhD
Contact
psteinert@mcw.edu
414-805-0700
Stephanie Farnia
Contact
sfarnia@nmdp.org
763-406-8640
Wael Saber, MD
study chair · Medical College of Wisconsin
Laura Michaelis, MD
study chair · Medical College of Wisconsin

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion